

Listing of Claims:

1. (currently amended) A method of producing a derivatised antibody, which derivatised antibody is capable of binding to an immobilised IgG, the method comprising:
treating a precursor antibody to expose a carbohydrate chain of the precursor antibody from an interstitial site on ~~the~~a surface of the precursor antibody; and,
chemically derivatising one or more amino acid residues of the precursor antibody to prevent the carbohydrate from returning to the interstitial site so that ~~the~~a resulting derivatised antibody is capable of binding to the immobilised IgG.
2. (original) The method of claim 1, wherein the precursor antibody has Fc associated carbohydrate chains which terminate with an N-acetylglucosamine residue.
3. (previously presented) The method of claim 1, comprising treating the precursor antibody with β -galactosidase to remove terminal galactose residues.
4. (previously presented) The method of claim 1, wherein the chemical derivatising comprises thiolating the antibody in the presence of carbonate.
5. (previously presented) The method of claim 1, comprising separating derivatised antibodies which ~~stack~~can associate with one another at a site of the immobilised IgG, from those derivatised antibodies which do ~~cannot~~ so ~~stack~~associate.
6. (previously presented) The method of claim 5, wherein separating the derivatised antibodies is performed by Con A chromatography or by pH elution from a Protein A affinity column.
7. (withdrawn) A derivatised antibody made by the method of claim 1, wherein the derivatised antibody is derivatised to expose a carbohydrate chain thereof, so that the derivatised antibody is capable of binding to the immobilised IgG.
8. (withdrawn) The derivatised antibody of claim 7, wherein the carbohydrate chain is an Fc carbohydrate chain.
9. (withdrawn) The derivatised antibody of claim 7, wherein the carbohydrate chain terminates with an N-acetylglucosamine residue.

10. (withdrawn) The derivatised antibody of claim 7, wherein the carbohydrate chains of the derivatised antibody are capable of specifically binding to a binding site on the derivatised antibody, when said derivatised antibody is immobilised.

11. (withdrawn) The derivatised antibody of claim 7, wherein the immobilised IgG is a galactosyl IgG.

12. (withdrawn) The derivatised antibody of claim 7, wherein the derivatised antibody is conjugated to a label, toxin, drug, prodrug or effector.

13. (withdrawn) The derivatised antibody of claim 7, wherein the derivatised antibody is specific for an inflammatory mediator.

14. (withdrawn) The derivatised antibody of claim 7, wherein the derivatised antibody is formulated for medical treatment or for diagnosis of a condition associated with the immobilised IgG.

15. (withdrawn) The derivatised antibody of claim 14, wherein the derivatised antibody provides for the diagnosis or treatment of an autoimmune disorder.

16. (withdrawn) The derivatised antibody of claim 15, wherein the autoimmune disorder is selected from the group consisting of: rheumatoid arthritis, juvenile arthritis, Crohn's disease, type I insulin dependent diabetes, type II diabetes, sarcoidosis, erythema nodosum leprosum, and tuberculosis.

17. (withdrawn) The antibody of claim 16, wherein the antibody is formulated for diagnosis or treatment of erosive joint disease and the immobilised IgG is anti-type II collagen IgG.

18. (withdrawn) A medicament comprising the derivatised antibody of Claim 7, which medicament treats or diagnoses a condition associated with immobilized IgG.

19. (withdrawn) The medicament of claim 18, wherein the condition associated with immobilised IgG is an autoimmune disorder.

20. (withdrawn) The medicament of claim 19, wherein the autoimmune disorder is selected from rheumatoid arthritis, juvenile arthritis, Crohn's disease, type I insulin dependent diabetes, type II diabetes, sarcoidosis, erythema nodosum leprosum and tuberculosis.

21. (withdrawn) The medicament of claim 18, wherein the condition is erosive joint disease and the immobilised IgG is anti-type II collagen IgG.

22. (withdrawn) A method for the in vivo diagnosis of a condition associated with immobilised IgG, the method comprising:


- a. exposing a Patient to the derivatised antibody of claim 7, which derivatised antibody has been labeled; and,
- b. detecting the label, thereby detecting the presence of the immobilised IgG.

23. (withdrawn) A pharmaceutical composition comprising a derivatised antibody made by the method of claim 1, and a carrier.

RADEMACHER, Thomas William et al.
Application No.: 09/622,253
Page 5

QUINE INTELLECTUAL PROPERTY LAW GROUP
P.O. BOX 458, Alameda, CA 94501
Tel: 510 769-3510
Fax: 510 337-7877
PTO Customer No.: **22798**
Deposit Account No.: **50-0893**

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Jonathan Alan Quine". The signature is fluid and cursive, with the first name "Jonathan" being more prominent than the last name "Quine".

Jonathan Alan Quine
Reg. No: 41,261

Attachments:

- 1) A transmittal sheet;
- 2) A receipt indication postcard.